基线18F-FDG PET放射组学特征在PET引导的弥漫性大B细胞淋巴瘤巩固治疗策略中的预后价值:GAINED研究的一项机器学习分析
该研究基于GAINED研究中的545例(2年PFS分类)和561例(生存分析)弥漫性大B细胞淋巴瘤患者,评估基线18F-FDG PET放射组学特征对接受PET引导巩固治疗策略患者生存的附加价值。机器学习分析显示,临床特征联合巩固治疗特征获得最佳AUC(0.72 ± 0.06),加入常规PET特征或放射组学特征并未改善结果;生存分析中临床联合巩固特征模型的log-rank P值显著小于所有联合特征组(P < 0.007)。结论认为多模态特征拼接结合简单机器学习模型似乎并未改善2年PFS分类和PFS预测。
要点
- 临床特征联合巩固治疗特征的AUC为0.72 ± 0.06,优于单独临床特征(0.65 ± 0.07)或单独巩固特征(0.64 ± 0.06)。
- 加入常规PET特征或放射组学特征并未改善2年PFS分类的AUC。
- 临床联合巩固特征模型的log-rank P值显著小于所有联合特征组(P < 0.007)。
核心结论
- 多模态特征拼接结合简单机器学习模型似乎并未改善按GAINED方案治疗患者的2年PFS分类和PFS预测结果。
研究设计与样本
- 基于GAINED研究,纳入545例患者进行2年PFS分类、561例进行生存分析,从基线18F-FDG PET提取常规PET特征和放射组学特征(按患者水平、最大病灶、最热病灶三种体积定义),并纳入临床特征和巩固治疗信息。
- 采用两种机器学习流程,以80%患者训练、剩余20%测试,训练重复100次以显示测试集变异性;2年PFS结局流程包括数据增强和弹性网络逻辑回归模型,生存结局流程包括Cox单变量模型筛选特征后基于惩罚Cox多变量系数回归评分的中位数将患者分为高风险和低风险。
- 不同特征组结果用平均AUC比较,100次循环的log-rank P值用Wilcoxon符号秩检验比较。
主要发现
- 仅临床特征、仅巩固治疗特征、常规PET特征、患者水平提取的放射组学特征AUC分别为0.65 ± 0.07、0.64 ± 0.06、0.60 ± 0.07、0.62 ± 0.07;最大病灶提取的放射组学特征AUC为0.62 ± 0.07,最热病灶为0.54 ± 0.07。
- 临床特征联合巩固治疗特征获得最佳AUC(0.72 ± 0.06)。
- 加入常规PET特征或放射组学特征并未改善结果。
- 生存分析中,临床联合巩固特征模型的log-rank P值显著小于所有联合特征组(P < 0.007)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The results of the GA in Newly Diagnosed Diffuse Large B-Cell Lymphoma (GAINED) study demonstrated the success of an 18F-FDG PET-driven approach to allow early identification-for intensification therapy-of diffuse large B-cell lymphoma patients with a high risk of relapse. Besides, some works have reported the prognostic value of baseline PET radiomics features (RFs). This work investigated the added value of such biomarkers on survival of patients involved in the GAINED protocol. Methods: Conventional PET features and RFs were computed from 18F-FDG PET at baseline and extracted using different volume definitions (patient level, largest lesion, and hottest lesion). Clinical features and the consolidation treatment information were also considered in the model. Two machine-learning pipelines were trained with 80% of patients and tested on the remaining 20%. The training was repeated 100 times to highlight the test set variability. For the 2-y progression-free survival (PFS) outcome, the pipeline included a data augmentation and an elastic net logistic regression model. Results for different feature groups were compared using the mean area under the curve (AUC). For the survival outcome, the pipeline included a Cox univariate model to select the features. Then, the model included a split between high- and low-risk patients using the median of a regression score based on the coefficients of a penalized Cox multivariate approach. The log-rank test P values over the 100 loops were compared with a Wilcoxon signed-ranked test. Results: In total, 545 patients were included for the 2-y PFS classification and 561 for survival analysis. Clinical features alone, consolidation features alone, conventional PET features, and RFs extracted at patient level achieved an AUC of, respectively, 0.65 ± 0.07, 0.64 ± 0.06, 0.60 ± 0.07, and 0.62 ± 0.07 (0.62 ± 0.07 for the largest lesion and 0.54 ± 0.07 for the hottest). Combining clinical features with the consolidation features led to the best AUC (0.72 ± 0.06). Adding conventional PET features or RFs did not improve the results. For survival, the log-rank P values of the model involving clinical and consolidation features together were significantly smaller than all combined-feature groups (P < 0.007). Conclusion: The results showed that a concatenation of multimodal features coupled with a simple machine-learning model does not seem to improve the results in terms of 2-y PFS classification and PFS prediction for patient treated according to the GAINED protocol.
引用
- Carlier T, Frécon G, Mateus D, et al. Prognostic Value of 18F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study. J Nucl Med. 2024. PMID: 37945379. doi:10.2967/jnumed.123.265872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。